Oncotarget

Research Papers:

The phosphorylation status of VASP at serine 322 can be predictive for aggressiveness of invasive ductal carcinoma

Heike Döppler _, Ligia Bastea, Sahra Borges, Xochiquetzal Geiger and Peter Storz

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2015; 6:29740-29752. https://doi.org/10.18632/oncotarget.4965

Metrics: PDF 578 views  |   HTML 1085 views  |   ?  


Abstract

Heike Döppler1,*, Ligia Bastea1,*, Sahra Borges1, Xochiquetzal Geiger2, Peter Storz1

1Department of Cancer Biology, Mayo Clinic Comprehensive Cancer Center, Mayo Clinic, Jacksonville, FL 32224, USA

2Pathology and Laboratory Medicine, Mayo Clinic, Jacksonville, FL 32224, USA

*These authors have contributed equally to this work

Correspondence to:

Peter Storz, e-mail: storz.peter@mayo.edu

Keywords: breast cancer, invasive, phosphorylation, VASP

Received: November 05, 2014     Accepted: July 31, 2015     Published: August 12, 2015

ABSTRACT

Vasodilator-stimulated phosphoprotein (VASP) signaling is critical for dynamic actin reorganization processes that define the motile phenotype of cells. Here we show that VASP is generally highly expressed in normal breast tissue and breast cancer. We also show that the phosphorylation status of VASP at S322 can be predictive for breast cancer progression to an aggressive phenotype. Our data indicate that phosphorylation at S322 is gradually decreased from normal breast to DCIS, luminal/ER+, HER2+ and basal-like/TN phenotypes. Similarly, the expression levels of PKD2, the kinase that phosphorylates VASP at this site, are decreased in invasive ductal carcinoma samples of all three groups. Overall, the phosphorylation status of this residue may serve as an indicator of aggressiveness of breast tumors.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 4965